### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

Nagambie Resources Limited		
ABN		
42 111 <u>5</u>	587 163	
We (tl	he entity) give ASX the following	information.
	1 - All issues ust complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Fully paid ordinary shares (Shares).
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,132,076 Shares.
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price	Shares are fully paid ordinary shares on the same terms as the existing fully paid ordinary shares on issue.

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

Shares will rank equally with the fully paid Do the \*securities rank equally in 4 all respects from the +issue date shares on issue. with an existing \*class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration \$0.053 per Share. 5 6 Purpose of the issue Shares issued under placement to (If issued as consideration for the professional and sophisticated investors. acquisition of assets, clearly identify those assets) 6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder 23 November 2018. resolution under rule 7.1A was passed 6c Number of \*securities issued 1,132,076 Shares. without security holder approval under rule 7.1 Nil. 6d Number of \*securities issued with security holder approval under rule 7.1A

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil.	
6f	Number of *securities issued under an exception in rule 7.2	Nil.	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 Capacity: 52,734,59. 7.1A Capacity: 43,577,7	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	15 November 2019	
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	438,539,878	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
INUITIDEI	C1055
10,100,000	Options exercisable at \$0.10 vesting 28 November 2014 and expiring on 28 November 2019.
3,300,000	Options exercisable at \$0.10 vesting 29 October 2015 and expiring on 16 November 2020.
8,000,000	Options exercisable at \$0.10 vesting 16 November 2015 and expiring on 16 November 2020.
2,000,000	Options exercisable at \$0.255 vesting 4 July 2016 and expiring on 4 July 2021.
12,500,000	Options exercisable at \$0.25 vesting 30 November 2016 and expiring on 30 November 2021.
13,750,000	Options exercisable at \$0.10 vesting 24 November 2017 and expiring on 24 November 2022.
1,000,000	Options exercisable at \$0.141 vesting 20 December 2017 and expiring on 20 December 2022.
4,500,000	Options exercisable at \$0.126 vesting 22 August 2018 and expiring on 22 August 2023.
10,500,000	Options exercisable at \$0.108 vesting 23 November 2018 and expiring on 23 November 2023.
2,000,000	Options exercisable at \$0.12 vesting 27 February 2019 and expiring on 27 February 2024.
18,680,000	Convertible notes each convertible into 1 ordinary share on or before 15 April 2020.
3,333,333	Convertible notes each convertible into 1 ordinary share on or before 17 September 2021.
18,000,000	Convertible notes each convertible into 1 ordinary share on or before 17 November 2022.
7,000,000	Convertible notes each convertible into 1 ordinary share on or before 27 February 2024.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

The Directors of the Company may from time to time determine to distribute the profits of the Company by way of dividend amongst the Shareholders in proportion to the amounts paid up on the Shares held by them.

#### Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
	B 1.1 .1	27/4
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different	N/A
	registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements	N/A
	in relation to fractions	
18	Names of countries in which the	N/A
	entity has security holders who will not be sent new offer	
	documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 14/03/2017

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	N/A
33	<sup>+</sup> Issue	e date	N/A
		Iotation of securities	
34	Type (tick	of *securities one)	
(a)		<sup>+</sup> Securities described in Part	1
(b)		*	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible
		have ticked box 34(a) ecurities forming a new	class of securities
Tick to docume		e you are providing the informat	ion or
35			securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36			securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		NT 1	+01
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

Appendix 3B Page 8 14/03/2017

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 15 November 2019

(Company secretary)

Print name: Alfonso Grillo

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	435,777,802	
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid</li> </ul>	Nil	
†ordinary securities cancelled during that 12 month period	INII	
"A"	435,777,802	

Appendix 3B Page 10 14/03/2017

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	65,366,670	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of +equity securities issued	2,500,000 options (23 November 2018)	
or agreed to be issued in that 12 month period <i>not counting</i> those issued:	7,000,000 convertible notes (27 February 2019)	
• Under an exception in rule 7.2	2,000,000 options (27 February 2019)	
Under rule 7.1A	1,132,076 shares (15 November 2019)	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	12,632,076	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-	
"A" x 0.15	65,366,670	
Note: number must be same as shown in Step 2		
Subtract "C"	12,632,076	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	52,734,594	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Step 1 of Part 1  Step 2: Calculate 10% of "A"		
"D"	0.10  Note: this value cannot be changed	
Multiply "A" by 0.10	43,577,780	
Step 3: Calculate "E", the amount 7.1A that has already been used  Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	or processors and a rate	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> </ul>		
<ul> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		

Appendix 3B Page 12 14/03/2017

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	43,577,780	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	43,577,780	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.